Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530240 | 0.87 | BCHE (0.83) | KMT2ALMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5532737 | 0.81 | KMT2A (0.74) | KMT2ALMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8237346 | 0.80 | BCHE (0.80) | KMT2ALMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5529457 | 0.80 | HTT (0.80) | ACACBKMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL8237905 | 0.80 | KMT2A (0.84) | KMT2ALMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5529214 | 0.78 | HTT (0.89) | ACACBKMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL5529559 | 0.77 | KMT2A (0.83) | KMT2ALMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14437452 | 0.77 | KMT2A (0.69) | KMT2ALMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5534950 | 0.75 | KDM4E (0.89) | KMT2ALMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5527493 | 0.75 | KMT2A (0.61) | KMT2ALMNAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | ACACB 2337/4885KMT2A 2807/4885HTT 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.